Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma

Clair, William H. St.; Adams, Judy; Bues, Martin; Fullerton, Barbara C.; Shell, S La; Kooy, Hanne M.; Loeffler, Jay S.; Tarbell, Nancy J.

doi:10.1016/s0360-3016(03)01574-8

Cited by 324 publications

(183 citation statements)

References 34 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…In a study performed by the MGH group, treatment plans utilising standard photon therapy, IMRT, or protons for craniospinal axis irradiation and posterior fossa boost were compared in a patient with medulloblastoma (St Clair et al, 2004). Substantial normal tissue sparing was realised with IMRT and proton irradiation of the posterior fossa and spinal axis.…”

Section: Paediatric Malignanciesmentioning

confidence: 99%

Proton beam therapy

et al. 2005

View full text Add to dashboard Cite

Conventional radiation therapy directs photons (X-rays) and electrons at tumours with the intent of eradicating the neoplastic tissue while preserving adjacent normal tissue. Radiation-induced damage to healthy tissue and second malignancies are always a concern, however, when administering radiation. Proton beam radiotherapy, one form of charged particle therapy, allows for excellent dose distributions, with the added benefit of no exit dose. These characteristics make this form of radiotherapy an excellent choice for the treatment of tumours located next to critical structures such as the spinal cord, eyes, and brain, as well as for paediatric malignancies.

show abstract

Section: Paediatric Malignanciesmentioning

confidence: 99%

Proton beam therapy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…We propose a simple method that allows one to determine the dose averaged LET value at each point along the measured Bragg peak. Instead of integrating proton spectra with proton stopping power along each track, we take the ratio of the energy deposited per unit length to proton beam fluence (see Equation (2)) to define dose averaged LET. Assuming that the RBE-LET relationship is known, we can then calculate RBE values along the measured pristine Bragg peak to construct a "biological", or RBE-weighted pristine Bragg peak.…”

Section: Methodsmentioning

confidence: 99%

“…The main focus of this paper is to develop a computational method for RBE based on dose averaged LET (see Equation (2)) values from a measured depth dose data for clinical beam. While for the same treatment range Bragg peak shape may differ between different treatment centers, we do expect that the method presented here is universally applicable for converting measured Bragg peaks into RBE-weighted Bragg peaks.…”

Section: Introductionmentioning

confidence: 99%

Biological Dose Estimation Model for Proton Beam Therapy

Anferov¹,

Das²

2015

IJMPCERO

View full text Add to dashboard Cite

Purpose: The recommended value for the relative biological effectiveness (RBE) of proton beams is currently assumed to be 1.1. However, there is increasing evidence that RBE increases towards the end of proton beam range that may increase the biological effect of proton beam in the distal regions of the dose deposition. Methods: A computational approach is presented for estimating the biological effect of the proton beam. It includes a method for calculating the dose averaged linear energy transfer (LET) along the measured Bragg peak and published LET to RBE conversion routine. To validate the proposed method, we have performed Monte Carlo simulations of the pristine Bragg peak at various beam energies and compared the analysis with the simulated results. A good agreement within 5% is observed between the LET analysis of the modeled Bragg peaks and Monte Carlo simulations. Results: Applying the method to the set of Bragg peaks measured at a proton therapy facility we have estimated LET and RBE values along each Bragg peak. Combining the individual RBE-weighted Bragg peaks with known energy modulation weights we have calculated the RBE-weighted dose in the modulated proton beam. The proposed computational method provides a tool for calculating dose averaged LET along the measured Bragg peak. Conclusions: Combined with a model to convert LET into RBE, this method enables calculation of RBE-weighted dose both in pristine Bragg peak and in modulated beam in proton therapy.

show abstract

“…Proton therapy has been known for the capability of delivering highly precise radiation doses to tumor volumes while protecting healthy tissue from radiation side effects for better outcomes 1 , 2 . However, this advanced technology has not been widely accepted because of: i) cost, exceeding $150 million for multiroom systems, ii) the space required to host accelerator, beamline, transport systems, and treatment rooms, and iii) complex delivery systems that require engineers specially trained and certified to run and maintain.…”

Section: Introductionmentioning

confidence: 99%

Commissioning and initial experience with the first clinical gantry‐mounted proton therapy system

Zhao

Sun

Grantham

et al. 2016

J Applied Clin Med Phys

View full text Add to dashboard Cite

The purpose of this study is to describe the comprehensive commissioning process and initial clinical experience of the Mevion S250 proton therapy system, a gantry‐mounted, single‐room proton therapy platform clinically implemented in the S. Lee Kling Proton Therapy Center at Barnes‐Jewish Hospital in St. Louis, MO, USA. The Mevion S250 system integrates a compact synchrocyclotron with a C‐inner gantry, an image guidance system and a 6D robotic couch into a beam delivery platform. We present our commissioning process and initial clinical experience, including i) CT calibration; ii) beam data acquisition and machine characteristics; iii) dosimetric commissioning of the treatment planning system; iv) validation through the Imaging and Radiation Oncology Core credentialing process, including irradiations on the spine, prostate, brain, and lung phantoms; v) evaluation of localization accuracy of the image guidance system; and vi) initial clinical experience. Clinically, the system operates well and has provided an excellent platform for the treatment of diseases with protons.PACS number(s): 87.55.ne, 87.56.bd

show abstract

Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma

Cited by 324 publications

References 34 publications

Proton beam therapy

Proton beam therapy

Biological Dose Estimation Model for Proton Beam Therapy

Commissioning and initial experience with the first clinical gantry‐mounted proton therapy system

Contact Info

Product

Resources

About